Hypoglycemic effect of Berberis microphylla G Forst root extract by Furrianca, María C. et al.
Furrianca et al 
Trop J Pharm Res, September 2017; 16(9): 2179  
 
Tropical Journal of Pharmaceutical Research September 2017; 16 (9): 2179-2184 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v16i9.19 
Original Research Article 
 
 
Hypoglycemic effect of Berberis microphylla G Forst root 
extract 
 
María C Furrianca1,2, Marysol Alvear3, Tomás Zambrano2, Víctor Fajardo4 and 
Luis A Salazar2* 
1Nursing Department, Universidad de Magallanes, Punta Arenas, Chile; 2Center of Molecular Biology and Pharmacogenetics, 
Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera, Temuco, Chile; 3Center of 
Amelioration and Sustainability of Volcanic Soils, Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de 
La Frontera, Temuco, Chile; 4Department of Science and Natural Resources, Universidad de Magallanes, Punta Arenas, Chile 
 
*For correspondence: Email: luis.salazar@ufrontera.cl; Tel: +56 45 259 6724 
 
Sent for review: 15 February 2017        Revised accepted: 17 August 2017 
 
Abstract 
Purpose: To evaluate the effect of the root extract of Berberis microphylla on glucose uptake and 
AMPK-activated protein kinase (AMPK) activity in non-resistant and insulin-resistant HepG2 cells. 
Methods: B. microphylla root was extracted with absolute ethanol, filtered, concentrated and 
lyophilized. Subsequently, liver cells, HepG2 (resistant and non-insulin resistant), were exposed for 24 h 
to different concentrations of the extract (10, 5, 2.5 and 1.25 x 10-3 μg/μL) to determine the stimulation of 
glucose uptake and phosphorylation of AMPK. 
Results: In HepG2 cells without resistance exposed to B. microphylla root extract, glucose uptake 
varied from 34 to 59 % of the available glucose while AMPK phosphorylation was 1.9 to 3.6 times the 
phosphorylation of the control. In insulin-resistant HepG2 cells, glucose uptake varied from 68 to 95 % 
of available glucose while AMPK phosphorylation was 1.8 to 3.3 times the phosphorylation of the 
control. 
Conclusion: The root extract of B. microphylla possesses hypoglycemic effects  and stimulates glucose 
uptake in HepG2 cells with and without resistance by activating AMPK protein.  
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Type 2 diabetes mellitus (T2DM) is a highly 
prevalent pathology, which has become a major 
public health problem worldwide [1]. Currently, it 
is considered a global epidemic since its 
prevalence has tripled during the last 30 years 
[2]. T2DM is a metabolic disorder characterized 
by high levels of blood glucose due to a 
deficiency in the action and secretion of insulin 
[3]. In the last years, AMP-activated protein 
kinase (AMPK) has been shown to be involved in 
regulating the energy balance by controlling the 
metabolism of glucose and lipids [4]. At present, 
several drugs that target AMPK are available for 
the treatment of T2DM [5], foremost among them 
metformin (first-line drug for the treatment of 
T2DM) [6]. Lamentably, 30 % of patients do not 
respond favorably to this treatment because they 
develop digestive disorders (diarrhea and 
vomiting), which can cause the discontinuation of 
the treatment with this drug [7]. Thus, the search 
for new alternative medicines for the treatment of 
this pathology is necessary. The Berberis genus 
has emerged as a phytotherapeutic alternative 
as several species of this genus are described as 
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having hypoglycemic potential, such as B. 
lycium, B. aristata, B. asiatica, B. vulgaris, B. 
integerrima, B. ceratophylla, B. moranensis and 
B. crataegina [8]. 
 
B. microphylla G. Forst is a South American 
species that has been utilized in ethno medicine 
for the treatment of febrile states, gastric pain 
and cold, among others [9]. At present, it is used 
as an alternative medicine for the treatment of 
T2DM. However, no scientific study assessing 
the antidiabetic activity of this plant has been 
reported. Therefore, the objective of this study is 
to evaluate the effect of B. microphylla root 
extract on glucose uptake and AMPK activity in 




Extract preparation  
 
The roots of B. microphylla were collected in the 
settlement of Bahía Mansa (53° 36’ 39, 38’’ S 
and 70° 55’ 50, 56’’ O) near the city of Punta 
Arenas, Chile. A sample of the species was 
identified by Dr Juan Marcos Henríquez, botanist 
and taxonomist at the Instituto de la Patagonia, 
Universidad de Magallanes, Chile (voucher no. 
012837). The collected roots were cut up and 
dried at room temperature for 30 days; 
subsequently, the pieces were ground and 100 g 
of the dried root were extracted with 1000 mL 
absolute ethanol for 72 h at room temperature. 
The extract was filtered and concentrated in a 
rotary evaporator at 40 °C. Finally, it was 
lyophilized and stored at 4 °C until use. 
 
HepG2 cell line 
 
HepG2 cells were purchased from the American 
Type Culture Collection (ATCC). Cells were 
maintained at 37 °C in a 5 % CO2 atmosphere in 
low glucose DMEM medium (1 mg/mL glucose), 
supplemented with 10 % fetal bovine serum 
(FBS), penicillin (100 U/mL) and streptomycin 
(100 μg/mL). Prior to each experiment, the cells 
were plated in 96-well plates at a density of 104 
cells/well. The growth medium was replaced with 
medium supplemented with 1 % FBS; and 
different concentrations of the root extract of B. 
microphylla, Metformin® (Mt) and Berberine® (Bb) 




HepG2 cells were seeded into 96-well multi-
plates under the conditions previously described. 
Subsequently, the medium was removed, and 20 
μL of (4,5-dimethylthiazol-2-yl) -2,5-diphenyl-
tetrazolium (MTT, 5 mg/mL) was added to each 
well and incubated for 4 h. The resultant 
formazan crystals were dissolved in 200 μL of 
dimethylsulfoxide (DMSO). Optical density (OD) 




HepG2 cell models without resistance were 
seeded into 96-well plates for 24 h under the 
conditions previously described. B. microphylla 
root extract (10, 5, 2.5 y 1.25 x 10-3 μg/μL), Mt 
(0.25 x 10-3 µg/µL) and Bb (0.25 x 10-3µg/µL) 
were added to the fresh medium at different 
concentrations in respective wells. The control 
consisted of cells without treatment. 
 
The glucose consumption was quantified using 
the enzymatic-colorimetric method GOD-PAP 
(Glucose Liquicolor, Germany). Quantification of 
glucose uptake was calculated by obtaining the 
difference between the initial glucose content (t = 
0 h) and the final glucose content (t = 24 h) in the 
medium. 
 
Insulin resistance in HepG2 cells was induced 
following the method previously described by Xie 
et al [10], with modifications. The cells were 
seeded into 96-well -plates with fresh medium, 
which contained 2 % FBS, 1 % antibiotic and 100 
nM bovine insulin for 24 h. The resistance was 
confirmed by control cells without treatment 
(without insulin). Subsequently, the medium was 
replaced with a medium containing 2 % FBS, 1 
% antibiotic and B. microphylla root extract at 
different concentrations (10, 5, 2.5 y 1.25 x 10-3 
μg/μL), Mt (0.25 x 10-3 µg/µL) and Bb (0.25 x 10-3 




HepG2 cell model without and with resistance 
were exposed to different concentrations of B. 
microphylla root extract (10, 5, 2.5 y 1.25 x 10-3 
μg/μL), Mt (0.25 x 10-3 µg/µL) and Bb (0.25 x 10-3 
µg/µL). Subsequently, glucose consumption was 
quantified. To determine the degree of AMPK 
phosphorylation in the cells, the Enzy FluoTM 
AMPK phosphorylation assay kit (EAMPK-100) 





All data are expressed as mean ± standard 
deviation (SD). Statistical analysis was 
performed using one-way analysis of variance 
(ANOVA), followed by Duncan's multiple range 
method. Values were considered statistically 
significant when p < 0.05. 
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HepG2 cells viability vs. exposure to extract 
of B. microphylla root, Mt and Bb 
 
The percentage of viability of HepG2 cells, which 
had been exposed to different concentrations of 
B. microphylla root extract, Mt and Bb, was 
determined through the use of the MTT test, 
using cells without treatment as control. Table 1 
shows that 100 % viability of HepG2 cells 
exposed to B. microphylla root extract occurs at 
a 10 x 10-3 μg/μL concentration. Starting from 
this concentration, the following tests were 
carried out using lower concentrations. On the 
other hand, as shown in Table 2, 100 % cell 
viability after exposure to Mt occurs at a 
concentration of 4 x 10-3 μg/μL, and with Bb 
occurs at a concentration 0.25 x 10-3 µg/µl. 
Therefore, for comparative purposes in the 
following assays, this latter concentration will be 
chosen for both compounds. 
 
Table 1: Cell viability of HepG2 cells treated with B. 




Cell viability  
(treated with B. microphylla) 
(%*, mean ± SD) 
Control 100 ± 0 
2.5 100 ± 9.1 
5 100 ± 8.6 
10 100 ± 2.4 
20 91.3 ± 6.5 
40 65.2 ± 9 
80 48.0 ± 1.0 
160 35.5 ± 1.3 
*Data expressed as % viability compared to control 
cells (100% survival); data are mean + SD (n = 3) 
 




(x 10-3 µg/µL) 
Cell viability 
(treated with Mt) 
Cell viability  
(treated with Bb) 
(%*, mean ± SD) (%*, mean ± SD) 
Control 100 ± 0 100 ± 0 
0.25 100 ± 4.6 100 ± 2.2 
0.5 100 ± 5.6 83.9 ± 8.3 
1 100 ± 7.3 82.89 ± 2.7 
2 100 ± 5.1 61.09 ± 2.2 
4 100 ± 6.3 57.6 ± 2.4 
8 97.9 ± 3.2 42.2 ± 4.2 
16 93.3 ± 2.3 38.2 ± 2.9 
*Data expressed as % viability compared to control 
cells (100% survival); data are mean + SD (n = 3) 
 
Glucose consumption stimulation  
 
The percentage of glucose consumption in non-
insulin-resistant and insulin-resistant HepG2 cells 
stimulated with B. microphylla root extract, Bb 
and Mt, was determined for a period of 24 h. It 
was observed that B. microphylla root extract, Bb 
and Mt significantly stimulated glucose 
consumption at all concentrations tested with 
respect to the control for both cells models. This 
finding determines a positive correlation between 
the dose of B. microphylla root extract and 
glucose uptake. 
 
In the non-resistant HepG2 cells, B. microphylla 
root extract increased glucose uptake statistically 
significantly (different letters) by 59, 53, 45 and 
34 % in the concentrations of 10, 5, 2.5 and 1.25 
(x10-3) µg/µl, respectively, as shown in Figure 1. 
The response to Bb and Mt, equally, was 
significant with respect to the control. 
 
In resistant HepG2 cells, the percentage of 
glucose uptake increased significantly (different 
letters) by 95, 91, 84 and 68 % for the 
concentrations of 10, 5, 2.5 y 1.25 x 10-3 µg/µl, 
(Figure 1), respectively.  Bb and Mt increased the 
percentage of glucose uptake by 73 and 81 %, 
which is likewise statistically significant. 
 
AMPK activation  
 
To determine the stimulation pathway of B. 
microphylla root extract, the activation of AMPK 
in HepG2 cells (non-insulin-resistant and with 
insulin-resistant) was assessed. As shown in 
Figure 2, the stimulation of AMPK by B. 
microphylla root extract in both cell models is 
statistically significant in all tested concentrations 
(different letters) as opposed to the control 
(untreated cells). A dose-response relationship 
was generated; that is to say, as the 
concentration of B. microphylla root extract 
increases, the stimulation of AMPK grows as 
well. In non-resistant HepG2 cells, B. microphylla 
root extract significantly increases AMPK 
phosphorylation to 3.6, 2.7, 2.3 and 1.9 times 
more than the phosphorylation in the control at 
all doses tested, 10, 5, 2.5 y 1.25 x 10-3 µg/µl, 
respectively. Bb and Mt also significantly 
stimulate the phosphorylation of AMPK to 2.9 
and 1.7 times more than the phosphorylation in 
the control.  
 
In insulin-resistant HepG2 cells exposed to the B. 
microphylla root extract, the stimulation of AMPK 
at the doses 10, 5, 2.5 y 1.25 x 10-3 µg/µl was 
3.3, 2.5, 2.2 and 1.8 times greater than that of 
the control, respectively. The AMPK response 
stimulated by Bb and Mt was also 2.8 and 1.7 
times greater than that of the control. All the 
responses differ significantly from the control. 
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Figure 1: Glucose uptake in insulin-resistant and non-resistant HepG2 cells exposed to different 
concentrations of B. microphylla root extract, Mt and Bb. Different letters (A, B, C, D for insulin-




Figure 2: Activation of AMPK protein phosphorylation by exposure to the extract of B. microphylla root, Mt and 
Bb in insulin-resistant and non-resistant HepG2 cells. Different letters (A, B, C, D for insulin-resistant cell and a, 




Berberis genus has been used as an alternative 
therapy for the treatment of diabetes or as a 
hypoglycemic agent by several indigenous 
peoples around the world. From here, the genus 
potentially emerges as a drug to combat this 
pathology [8]. In the literature, there are several 
reports, developed mainly in animal models, 
which highlight the hypoglycemic activity of the 
Berberis genus. These works show that this plant 
species generates a decrease in blood glucose 
levels in different murine species [11–19]. 
Berberine, the active compound of this species, 
is also described as a glucose uptake stimulator 
in HepG2 cells [20]. Similarly, the root extract of 
B. microphylla stimulates the uptake of glucose 
in HepG2 cells, beginning with the tested 
concentration of 1.25 x 10-3 μg/μL; the root 
extract also exerts this same effect on resistant 
hepatic cells at the sameextract also exerts this 
same effect on resistant hepatic cells HepG2 at 
the same concentration and in both cases 
generates a dose-dependent response. 
 
With respect to possible mechanisms of action, 
B. julianae extract has been shown to increase 
translocation and expression of glucose 
transporter GLUT4 in muscle cells L6, causing 
increased glucose uptake as well as increasing 
the phosphorylation of AMPK in the hepatic and 
muscular tissue of mice [21]. In the same 
manner, it has been demonstrated in mouse 
muscle cells that berberine is involved in the 
activation of AMPK and p38 MAPK [22]. 
 
When exposing HepG2 cells with and without 
insulin resistance to different concentrations of B. 
microphylla root extract, an increasing AMPK 
phosphorylation in both experiments could be 
determined, which generated a positive 
correlation; that is to say, as the extract 
concentration increased, the phosphorylation of 
AMPK also grew. 
 
This may happen because the increase in the 
activity of AMPK in hepatic cell lines leads to a 
decrease in the expression of glucose-6-
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phosphatase (G6Pase) mediated by post-
translational silencing of its transcription factor, 
FOXO1a [23,24]. However, further studies are 
still needed to clarify this mechanism of 
repression. 
 
AMPK acts as a master metabolic switch in 
response to alterations in the cellular energy load 
and plays an important role in energy 
homeostasis through the coordination of adaptive 
responses in low energy metabolic states [25]. In 
the literature, there have been a number of 
reports on AMPK activators, such as AICAR, 
metformin, rosiglitazone and leptin, as well as 
natural products including berberine, caffeic acid 
phenethyl ester (CAPE), epigallocatechin-3-
gallate (EGCG), nicotine, β-sitosterol, and 
corosolic acid, which have been used as 





We can affirm that the root extract of B. 
microphylla would have beneficial therapeutic 
effects against diabetes because it is capable of 
increasing glucose consumption under conditions 
of no resistance and insulin resistance. The 
possible mechanism of action would be the 
stimulation of AMPK. This mechanism explains, 
in part, why B. microphylla would show 
hypoglycemic activity and may be used in the 
treatment of type 2 diabetes mellitus. However, 
further research is needed for a complete 
understanding of the underlying actions of its 
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